A recent study reported that breast cancer stem cells were inhibited by benztropine mesylate in vitro by using stem cell markers such as aldehyde dehydrogenase activity, CD44+/CD24- phenotype, and the number of spheroids [32]. This evidence concerns the gene CD44 and breast carcinoma.